12:00 AM
Mar 19, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

GALNS: Completed Phase III enrollment

BioMarin completed enrollment of 176 patients in a double-blind, placebo-controlled, international Phase III trial to evaluate 2 mg/kg IV GALNS given...

Read the full 84 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >